Ustekinumab for children and adolescents with inflammatory bowel disease at a tertiary children's hospital in Japan.

Ichiro TakeuchiKatsuhiro AraiReiko KyodoTakuro SatoKazuhide TokitaYuri HiranoHirotaka Shimizu

Published in: Journal of gastroenterology and hepatology (2020)

Ustekinumab may be an effective and safe treatment option for pediatric and adolescent Crohn's disease and Crohn's disease-like inflammatory bowel disease patients having nonresponse or adverse reactions to anti-tumor necrosis factor agents.

Keyphrases

young adults
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
healthcare
rheumatoid arthritis
prognostic factors
emergency department
adverse drug
ulcerative colitis
patient reported outcomes
hidradenitis suppurativa